These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 30550537

  • 1. Serological and PCR-based markers of ocular Chlamydia trachomatis transmission in northern Ghana after elimination of trachoma as a public health problem.
    Senyonjo LG, Debrah O, Martin DL, Asante-Poku A, Migchelsen SJ, Gwyn S, deSouza DK, Solomon AW, Agyemang D, Biritwum-Kwadwo N, Marfo B, Bakajika D, Mensah EO, Aboe A, Koroma J, Addy J, Bailey R.
    PLoS Negl Trop Dis; 2018 Dec; 12(12):e0007027. PubMed ID: 30550537
    [Abstract] [Full Text] [Related]

  • 2. Surveillance for peri-elimination trachoma recrudescence: Exploratory studies in Ghana.
    Senyonjo L, Addy J, Martin DL, Agyemang D, Yeboah-Manu D, Gwyn S, Marfo B, Asante-Poku A, Aboe A, Mensah E, Solomon AW, Bailey RL.
    PLoS Negl Trop Dis; 2021 Sep; 15(9):e0009744. PubMed ID: 34543293
    [Abstract] [Full Text] [Related]

  • 3. Pgp3 seroprevalence and associations with active trachoma and ocular Chlamydia trachomatis infection in Malawi: cross-sectional surveys in six evaluation units.
    Burr SE, Hart J, Samikwa L, Chaima D, Cooley G, Martin D, Masika M, Solomon AW, Bailey RL, Kalua K.
    PLoS Negl Trop Dis; 2019 Oct; 13(10):e0007749. PubMed ID: 31658258
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prevalence of signs of trachoma, ocular Chlamydia trachomatis infection and antibodies to Pgp3 in residents of Kiritimati Island, Kiribati.
    Cama A, Müller A, Taoaba R, Butcher RMR, Itibita I, Migchelsen SJ, Kiauea T, Pickering H, Willis R, Roberts CH, Bakhtiari A, Le Mesurier RT, Alexander NDE, Martin DL, Tekeraoi R, Solomon AW, Global Trachoma Mapping Project.
    PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005863. PubMed ID: 28898240
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Serology for trachoma surveillance after cessation of mass drug administration.
    Martin DL, Bid R, Sandi F, Goodhew EB, Massae PA, Lasway A, Philippin H, Makupa W, Molina S, Holland MJ, Mabey DC, Drakeley C, Lammie PJ, Solomon AW.
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003555. PubMed ID: 25714363
    [Abstract] [Full Text] [Related]

  • 8. Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies.
    Migchelsen SJ, Martin DL, Southisombath K, Turyaguma P, Heggen A, Rubangakene PP, Joof H, Makalo P, Cooley G, Gwyn S, Solomon AW, Holland MJ, Courtright P, Willis R, Alexander ND, Mabey DC, Roberts CH.
    PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005230. PubMed ID: 28099433
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of the reproducibility of a serological test for antibodies to Chlamydia trachomatis pgp3: A potential surveillance tool for trachoma programs.
    Kaur H, Dize L, Munoz B, Gaydos C, West SK.
    J Microbiol Methods; 2018 Apr; 147():56-58. PubMed ID: 29501689
    [Abstract] [Full Text] [Related]

  • 10. Comparison of platforms for testing antibodies to Chlamydia trachomatis antigens in the Democratic Republic of the Congo and Togo.
    Gwyn S, Awoussi MS, Bakhtiari A, Bronzan RN, Crowley K, Harding-Esch EM, Kassankogno Y, Kilangalanga JN, Makangila F, Mupoyi S, Ngondi J, Ngoyi B, Palmer S, Randall JM, Seim A, Solomon AW, Stewart R, Togbey K, Uvon PA, Martin DL.
    Sci Rep; 2021 Mar 31; 11(1):7225. PubMed ID: 33790370
    [Abstract] [Full Text] [Related]

  • 11. Trachoma, Anti-Pgp3 Serology, and Ocular Chlamydia trachomatis Infection in Papua New Guinea.
    Macleod CK, Butcher R, Javati S, Gwyn S, Jonduo M, Abdad MY, Roberts CH, Keys D, Koim SP, Ko R, Garap J, Pahau D, Houinei W, Martin DL, Pomat WS, Solomon AW.
    Clin Infect Dis; 2021 Feb 01; 72(3):423-430. PubMed ID: 31965155
    [Abstract] [Full Text] [Related]

  • 12. Can We Use Antibodies to Chlamydia trachomatis as a Surveillance Tool for National Trachoma Control Programs? Results from a District Survey.
    West SK, Munoz B, Weaver J, Mrango Z, Dize L, Gaydos C, Quinn TC, Martin DL.
    PLoS Negl Trop Dis; 2016 Jan 01; 10(1):e0004352. PubMed ID: 26771906
    [Abstract] [Full Text] [Related]

  • 13. Serology, infection, and clinical trachoma as tools in prevalence surveys for re-emergence of trachoma in a formerly hyperendemic district.
    Odonkor M, Naufal F, Munoz B, Mkocha H, Kasubi M, Wolle M, West S.
    PLoS Negl Trop Dis; 2021 Apr 01; 15(4):e0009343. PubMed ID: 33861754
    [Abstract] [Full Text] [Related]

  • 14. Serology reflects a decline in the prevalence of trachoma in two regions of The Gambia.
    Migchelsen SJ, Sepúlveda N, Martin DL, Cooley G, Gwyn S, Pickering H, Joof H, Makalo P, Bailey R, Burr SE, Mabey DCW, Solomon AW, Roberts CH.
    Sci Rep; 2017 Nov 08; 7(1):15040. PubMed ID: 29118442
    [Abstract] [Full Text] [Related]

  • 15. Control of Trachoma from Achham District, Nepal: A Cross-Sectional Study from the Nepal National Trachoma Program.
    Pant BP, Bhatta RC, Chaudhary JS, Awasthi S, Mishra S, Sharma S, Cuddapah PA, Gwyn SE, Stoller NE, Martin DL, Keenan JD, Lietman TM, Gaynor BD.
    PLoS Negl Trop Dis; 2016 Feb 08; 10(2):e0004462. PubMed ID: 26871898
    [Abstract] [Full Text] [Related]

  • 16. Serological Measures of Trachoma Transmission Intensity.
    Martin DL, Wiegand R, Goodhew B, Lammie P, Black CM, West S, Gaydos CA, Dize L, Mkocha H, Kasubi M, Gambhir M.
    Sci Rep; 2015 Dec 21; 5():18532. PubMed ID: 26687891
    [Abstract] [Full Text] [Related]

  • 17. Ongoing transmission of trachoma in low prevalence districts in Mozambique: results from four cross-sectional enhanced impact surveys, 2022.
    Sitoe HM, Oswald WE, Zita F, Fall M, Momade T, Adams MW, Flueckiger RM, McPherson S, Eyob S, Doan T, Lietman TM, Arnold BF, Wickens K, Gwyn S, Martin DL, Kasubi M, Boyd S, Bakhtiari A, Jimenez C, Solomon AW, Harding-Esch EM, Mwingira UJ, Ngondi JM.
    Sci Rep; 2024 Oct 15; 14(1):22842. PubMed ID: 39406720
    [Abstract] [Full Text] [Related]

  • 18. No Serological Evidence of Trachoma or Yaws Among Residents of Registered Camps and Makeshift Settlements in Cox's Bazar, Bangladesh.
    Cooley GM, Feldstein LR, Bennett SD, Estivariz CF, Weil L, Bohara R, Vandenent M, Mainul Hasan A, Akhtar MS, Uzzaman MS, Billah MM, Conklin L, Ehlman DC, Asiedu K, Solomon AW, Alamgir A, Flora MS, Martin DL.
    Am J Trop Med Hyg; 2021 May 03; 104(6):2031-2037. PubMed ID: 33939630
    [Abstract] [Full Text] [Related]

  • 19. Serological Responses to Trachoma Antigens prior to the Start of Mass Drug Administration: Results from Population-Based Baseline Surveys, North Darfur, Sudan.
    Sanders AM, Elshafie BE, Abdalla Z, Simmons C, Goodhew EB, Gonzalez TA, Nute AW, Mohammed A, Callahan EK, Martin DL, Nash SD.
    Am J Trop Med Hyg; 2024 Sep 03; 111(3_Suppl):49-57. PubMed ID: 38507810
    [Abstract] [Full Text] [Related]

  • 20. Population-Based Prevalence of Chlamydia trachomatis Infection and Antibodies in Four Districts with Varying Levels of Trachoma Endemicity in Amhara, Ethiopia.
    Nash SD, Astale T, Nute AW, Bethea D, Chernet A, Sata E, Zerihun M, Gessese D, Ayenew G, Ayele Z, Melak B, Haile M, Zeru T, Tadesse Z, Arnold BF, Callahan EK, Martin DL.
    Am J Trop Med Hyg; 2021 Jan 03; 104(1):207-215. PubMed ID: 33200728
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.